OncoSec Medical Inc (ONCSQ)

[hschlauch]

Hi Chick, just to clarify, that retrospective study was not specific to monotherapy pembrolizumab non-responders. The patient population was refractory to various prior therapies. In fact, only 2 out of 14 evaluable refractory patients were previously treated with pembrolizumab. A biomarker was not used to select or exclude patients.

The current combination trial that will report out next month with interim results, is selecting a non-responder (to monotherapy pembrolizumab) population. The trial design makes it much more difficult to obtain responses, i.e. because it is specifically selecting patients who will not respond to monotherapy pembrolizumab. Thus the 30% goal that PD threw out there is not comparable to the 64%-75% responses observed in the retrospective trial. Obtaining 30% in a NON-RESPONDER population is quite good and compares favorably to the best combinations observed in any other combination metastatic melanoma trial.